ACTRIMS 2022 | COVID-19 outcomes in patients with relapsing MS receiving cladribine
Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK, talks on the COVID-19 outcomes of patients with relapsing multiple sclerosis (MS) treated with cladribine in a Phase III trial. Overall, the study included 632 COVID-19 cases, 406 were confirmed, 226 were suspected and 60 of the cases were serious. Notably, a total of 4 deaths from COVID-19 occurred, a proportion lower than the average number of deaths from COVID-19 in the general population. The majority of patients recovered, and none required mechanical ventilation. It was therefore concluded that patients receiving cladribine are at no greater risk of severe outcomes compared to the general population and other MS populations. This interview took place at the ACTRIMS Forum 2022 in West Palm Beach, Florida.
Disclosures
In the last 5 years, Gavin Giovannoni has received compensation for serving as a consultant or speaker for or has received research support from AbbVie, Aslan, Atara Bio, Biogen, BMS-Celgene, GlaxoSmithKline, GW Pharma, Janssens/Actelion, Japanese Tobacco, Jazz Pharmaceuticals, LifNano, Merck & Co, Merck KGaA/EMD Serono, Novartis, Sanofi-Genzyme, Roche/Genentech and Teva.
